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T
he American College of Endocrinol-
ogyheldaConsensusConferencein
Washington, DC, on 21–22 July
2008 on the topic of pre-diabetes, orga-
nizedaroundaseriesofinterrelatedques-
tions. This is the second of a three-part
series summarizing presentations at the
conference.
What goals and treatment
modalities should be the focus of the
management of pre-diabetes? Does
early intervention make a difference?
Scott Grundy (Dallas, TX) and Christie
Ballantyne (Houston, TX) discussed as-
pects of the nonglycemic goals of pre-
diabetes treatment, addressing obesity,
bloodpressure,andlipidmanagement,as
wellasgoalsofthrombusprevention.Bal-
lantyne discussed the concept of the met-
abolic syndrome, pointing out that a
number of commonly measured clinical
variables may be used in predicting dia-
betes (such as waist circumference, hy-
pertension, family history of diabetes,
ethnicity, age, fasting glucose, and lipids
[1]) and suggesting that the metabolic
syndrome thus offers a practical means of
allowing physicians to integrate many of
these factors rather than itself adding to
risk. For cardiovascular disease predic-
tion, Ballantyne suggested, blood glucose
is less important than blood pressure and
HDL cholesterol, which are particularly
important, as metabolic syndrome com-
ponents (2); and, of course, LDL choles-
terol and cigarette use are additional
factors that must be taken into account.
Other measures, such as microalbumin-
uria, retinal abnormalities, A1C, C-reac-
tive protein, lipoprotein-associated
phospholipase A2, carotid ultrasound,
and coronary calcium score, may be use-
ful as well. Recognizing that 98% of
womenhaveaFraminghamriskscorebe-
low 10%, Ballantyne proposed redeﬁning
intermediate risk as between 5 and 20%
per decade.
Grundy described metabolic syn-
drome as a subtype of obesity, caused by
environmental (increased dietary calories
and lack of exercise) and genetic factors,
resultinginatherogenicdyslipidemia,hy-
pertension, a prothrombotic state, and
many other conditions, as well as pre-
diabetes. The National Health and Nutri-
tion Evaluation Survey II, carried out
from 1988 to 1994, showed substantial
overlap between pre-diabetes and meta-
bolic syndrome (3), which Grudy termed
the cardiovascular disease–centric and
glucose-centric views, suggesting the
need to address the combined syndrome.
Both metabolic syndrome without im-
paired fasting glucose (IFG) and IFG
without metabolic syndrome are associ-
ated with ﬁvefold increases in diabetes,
while the combination of both is associ-
ated with a 20-fold increase; thus, the
metabolic syndrome, with or without
IFG, may be considered a form of pre-
diabetes (4). Meta-analysis shows meta-
bolic syndrome to be associated with a
1.6- to 2.0-fold increase in a variety of
formsofcardiovasculardisease(5).Eight-
yearfollow-updatafromtheFramingham
Offspring Study similarly showed meta-
bolic syndrome without diabetes to be as-
sociated with high cardiovascular disease
risk for both women and men, with
womenhavingmetabolicsyndromealone
at somewhat greater risk than women
having type 2 diabetes alone.
Weight loss is an effective approach
to treatment of metabolic syndrome (6),
as is regular physical activity (7). Reason-
able lifestyle goals are for a 7–10% weight
loss and 30–60 min/day of regular mod-
erate-intensity physical activity. Antihy-
pertensive treatment with an average
reduction of 12–13 mmHg in systolic
blood pressure over 4 years of follow-up
was associated with a 21% reduction in
coronary heart disease, 37% reduction in
stroke, 25% reduction in total cardiovas-
cular mortality, and 13% reduction in all-
cause mortality in a pooled analysis of
randomized controlled trials (8). A reason-
able goal, if diabetes is present, is to achieve
blood pressure 130/80 mmHg (9) with
approaches including lifestyle, alcohol
moderation, sodium restriction, and phar-
macotherapy (renin-angiotensin system
agents primarily, as well as thiazides in low
doses; it should be noted that -blockers
may worsen insulin resistance).
Ballantyne reviewed beneﬁts of ad-
ministration of statins in metabolic syn-
drome (10), pointing out that with the
compelling evidence of statin beneﬁt, an
argumentmaybemadefavoringthemore
intensive statin treatment goals of LDL
andnon-HDLcholesterol70and100mg/
dl, respectively, and apolipoprotein B 80
mg/dl. Grundy reviewed a prospective
meta-analysis of data from 90,056 partic-
ipants in 14 randomized trials of statins
showing that for every 1 mmol/l lowering
of LDL cholesterol coronary disease mor-
tality decreased by 19% (11). The long-
term safety of statins has been conﬁrmed,
and statins are the ﬁrst-line agents for
lipid treatment. Grundy pointed out their
cost-effective beneﬁt, now that these
agents are available as generics, for indi-
viduals with a 5% 10-year risk, character-
izing their use as “like taking aspirin,
more or less.” The bile acid sequestrant
cholestyramine lowered LDL cholesterol
by 20% and reduced coronary heart dis-
ease death and/or deﬁnite nonfatal myo-
cardial infarction by 19% in the Lipid
Research Clinic trials (12). The agent also
lowered glucose levels, now conﬁrmed in
studies of colesevelam (13), which
“wouldn’t be a bad idea for a patient with
pre-diabetes.” Given bile acid seques-
trants’ action to increase triglycerides,
however, Ballantyne observed that com-
bination treatment using resins with nia-
cinmayoffercomplimentarybeneﬁtsand
offseteachother’ssideeffects,asnicotinic
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lar effect in several large trials [14]) raises
glucose (15). However, studies suggest
that diabetic patients have stable glucose
levels despite using this agent.
Fibric acids are particularly effective
with a high triglyceride/metabolic syn-
drome pattern, as was shown in the Vet-
erans Administration HDL Intervention
Trial, the Fenoﬁbrate Intervention and
Event Lowering in Diabetes Study, the
Bezaﬁbrate Infarction Prevention trial,
and the Helsinki trials. Fibrates lower
triglycerides and raise HDL cholesterol,
with evidence of reduction in albumin-
uria and retinopathy (16), although in-
creases in creatinine and homocysteine
may be issues; particularly, patients with
hyperinsulinemia may beneﬁt from ﬁ-
brates (17). n-3 fatty acids reduce triglyc-
erides and non-HDL cholesterol, and
some (18) but not all (19) studies show
reduction in end points with this treat-
ment. The cholesterol absorption inhibi-
tor ezetimibe still requires a clinical trial
to demonstrate safety and efﬁcacy. Goals
for individuals with established cardio-
vascular disease are 70 mg/dl for LDL
cholesteroland100mg/dlfornon-HDL
cholesterol and are 30 mg/dl higher with-
out established cardiovascular disease.
Although the Adult Treatment Panel III
guidelines would allow an LDL choles-
terol of 130 mg/dl as a goal for metabolic
syndrome and, by extension, pre-
diabetes, Grundy proposed that “most
people think that if you have metabolic
syndrome you ought to get the LDL to
100.”
Antiplatelet therapy reduces vascular
risk by 23%, with cost not a factor for
aspirin, and although there may be safety
issues with gastrointestinal and cerebral
hemorrhage,suchagentsshouldcertainly
be administered with 10-year major car-
diovascular disease event risk 10%
(20). Grundy summarized that from a
therapeutic view point, rather than con-
sidering metabolic syndrome and pre-
diabetes to be separate entities, “they
reallyshouldbecombinedintoone,inmy
view.”
Ralph DeFronzo (San Antonio, TX)
discussed approaches to early treatment
of diabetes, with focus on the role of thia-
zolidinediones (TZDs). He presented an
analysis of the development of diabetes
using the disposition index, calculated as
the ratio of insulin secretion to insulin re-
sistance. The data can be interpreted to
show that “pathophysiologically [peo-
plewithpre-diabetes]reallyhavetype2
diabetes,” having an 80% or greater re-
duction in this index. The relationship
between 2-h glucose disposition index,
DeFronzo said, “really [has] no cut
point....This is a physiologic contin-
uum.” He reviewed evidence that -cell
volume on autopsy studies is inversely
proportional to fasting glucose, decreas-
ingbyhalfatthestageofimpairedglucose
tolerance (IGT), with further progression
in individuals with type 2 diabetes (21).
Given the evidence of retinopathy and
neuropathy in IGT in the Diabetes Pre-
vention Program (DPP) reviewed by Rat-
ner (see part one of this series [22]),
DeFronzo suggested, “We need to inter-
vene early....I tw ould be ideal to be-
gin . . . long before we have IGT.”
Of therapeutic options, both met-
formin and TZDs are effective in the liver,
with TZDs to a greater extent than met-
formin having effect in muscle. When
both agents are administered in submaxi-
maldoses,weightgainandﬂuidretention
from the TZD are reduced, as are gastro-
intestinal side effects of metformin. A
number of drugs appear to have -cell
beneﬁts, including TZDs and perhaps
glucagon-like peptide (GLP)-1 receptor
activators. There is, DeFronzo said, no
deﬁnite evidence that dipeptidyl pepti-
dase-4 inhibitors beneﬁt -cell function.
Neither sulfonylureas nor metformin has
such an effect; both had an initial beneﬁt
and a subsequent rise in A1C in the UK
Prospective Diabetes Study and, particu-
larlyforsulfonylureas,inmanyadditional
studies. In a large study, -cell function
decreased6%peryearwithglyburidever-
sus2%peryearwithrosiglitazone(23).In
individuals with pre-diabetes, TZDs re-
duced conversion to type 2 diabetes by
52–81%.
DeFronzo described the Actos Now
for Prevention of Diabetes (ACT-NOW)
studyof602individualswithIGT,fasting
glucose 95 mg/dl, and one additional
risk factor. Subjects were randomized to
pioglitazone versus placebo, with annual
rates of diabetes development 1.5 vs.
6.8%, respectively, as well as a twofold
greater rate of conversion to normal glu-
cose tolerance (NGT) and improvement
in the disposition index. TZDs may di-
rectly affect -cells via action on peroxi-
some proliferator–activated receptor- or
may act indirectly by improving insulin
resistance, reducing free fatty acids, or re-
ducing glucose toxicity.
David Marrero (Indianapolis, IN) re-
viewed the lifestyle intervention of the
DPP.Eachpatientwasassignedapersonal
trainer,withsupervisedexercisesessions,
group classes, and motivational cam-
paigns using strategies including free ex-
ercise sneakers and even payments for
achieving behavioral goals: “a very well-
funded and resource-rich environment.”
Inninestudiesthathaveuseda“reduced”
DPPcurriculum,weightlosshasaveraged
2–5%, although one version of the DPP
curriculumofferedincommunitysettings
achieved a 6% weight loss that was main-
tained 12–14 months after the interven-
tion. “Until we do a little bit more
research,” he concluded, “we should stay
with the core curriculum.” He reviewed
the basic components of this curriculum.
Self-monitoring of food, drink, and ex-
ercise. “Everybody underestimates what
they eat,” Marrero said. We need to in-
crease patients’ awareness of behavior,
measure their progress, improve compli-
ance with behavior change, and identify
sources of excess calories.
Goalsetting. Inananalysisoftheweight
loss goals of 60 obese women, most felt
that loss of 25% of body weight would be
thelowestdegreeacceptableandthatthey
would be disappointed with a weight loss
of 17% (24). We need, then, to help pa-
tients establish realistic antecedent goals
by limiting eating places; reducing the
rate of food consumption; setting goals
NEWS FROM THE FOOD AND DRUG ADMINISTRATION
From time to time, new announcements by the FDA pertaining to aspects of diabetes
treatment will be highlighted in this section.
The FDA reported that patients who use icodextrin (Extraneal) for peritoneal
dialysis and glucose-monitoring devices and do not use a glucose-speciﬁc test
strip (including the Accu-Chek [Roche] and FreeStyle [Abbott]) will, because
maltose is a metabolic product of icodextrin, have elevated blood maltose levels
resulting in falsely elevated blood glucose readings. This may lead to inappro-
priate insulin administration, which has caused hypoglycemia, coma, and death
and may cause cases of true hypoglycemia to go untreated.
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tablishing consequence goals for relapse
prevention and rewards. Goals need to be
speciﬁc, manageable, and attainable.
Stimulus control. It is important to in-
creasecuesforhealthyeatingandexercise
and to decrease cues for overeating and
inactivity.
Cognitive strategies. An important as-
pectofthecurriculumistherestructuring
of maladaptive thought patterns to elimi-
nate the idea of “failing.”
Social support. Perception of support
correlates with weight loss, and including
spouses in a program modestly improves
success, with successful supporters par-
ticularlyhelpfulinparticipants’achieving
goals.
Reinforcement of success. It is impor-
tant to reward behavior as soon after the
accomplishmentaspossible.Evenifwith-
out weight loss, what was done correctly
should be identiﬁed and the patient
should be congratulated.
A summary analysis of nine trials has
shown 7–10% weight loss with such an
approach, although there is subsequent
weight gain (30% of patients regaining
quickly, but the remaining participants
also showing slow increase in body
weight). This is, of course, not just true of
the DPP protocol. In an analysis of out-
come of a number of programs, by 5
years, 50% or more of weight loss partic-
ipants have regained all or most of the
weight lost (25). “It’s the maintenance
that’s critical,” Marrero commented.
“That’s what we as a society have to
consider.”
The target population of pre-diabetic
adults can be linked with health plan/
employer physician reimbursement. In
addition, community institutions are of-
ten able to provide structured lifestyle in-
terventions to achieve 5–7% weight loss
and then ongoing behavior support at
least monthly. In the DPP, the interven-
tion cost was $1,476/ per patient-year,
but group-format interventions with a lay
instructor have been carried out for $243
per patient-year and it may be possible to
extend the approach to commercial and
internet-based weight loss programs.
Mary Parks of the Food and Drug Ad-
ministration (FDA) discussed regulatory
issues in approving pharmacotherapy of
pre-diabetes and reviewing new require-
ments for drug development in diabetes.
Therearecurrentlynodrugsapprovedfor
diabetes prevention, but the FDA draft
guidance statement for diabetes therapies
has issued a description of potential end
pointssupportingapprovalofsuchagents
relative to placebo, including a delay in
type 2 diabetes diagnosis by, for example,
AmericanDiabetesAssociation(ADA)cri-
teria, with comparison needed to assess
whether the proposed agent causes a du-
rable beneﬁt (26). When such an analysis
is undertaken with regard to acarbose in
STOP-type2diabetes,a25%reductionin
diabetes development was seen; met-
formin in the DPP, 31%; orlistat in the
XENical in the prevention of Diabetes in
Obese Subjects (XENDOS) study, 37%;
TZDs (as discussed by DeFronzo), 50–
80%; and lifestyle in the Da Qing study,
42%, and in both the DPP and Finnish
DPS, 58%. She considered the diagnosis
of diabetes based on a glucose tolerance
test(GTT),conﬁrmedwithrepeattesting,
tobeaclinicallymeaningfulendpointbut
stated that a question exists as to whether
pharmacological intervention with anti-
diabetes agents merely treats disease in
advance of its diagnosis, thereby masking
its detection. In STOP-type 2 diabetes, af-
tera3-monthwashout,15%ofthosewho
hadreceivedacarboseversus10.5%ofthe
placebo subjects developed diabetes, and
in the Troglitazone in Prevention of Dia-
betes (TRIPOD) study, at 3-year fol-
low-up there was similar incidence of
type 2 diabetes in patients formerly
treated with troglitazone versus those
who had received placebo. “Whether or
not this is evidence that these drugs are
not delaying progression to diabetes” is
uncertain, Parks noted, observing that “if
you stop therapies then the beneﬁt may
no longer be evident.”
What, she asked, constitute other
suitable end points? Safety end point
analysis is required to address drug risk.
Surrogate end points rather than clinical
beneﬁt end points include measures such
as weight loss, lipids, blood pressure, and
quality of life, but clinical outcome is
clearly more meaningful. In STOP-type 2
diabetes, cardiovascular disease out-
comes decreased, with hypertension also
developing less frequently, although
Parks observed that before accepting this
as an effect of -glucosidase inhibitors
“we do need some conﬁrmatory data.” To
appropriately determine whether a drug
treatment is appropriate for pre-diabetes,
we therefore must be able to address its
risk-beneﬁt ratio. As all drugs have some
risk, targeting an otherwise healthy pop-
ulation in which some individuals at risk
never develop diabetes requires special
caution and assessment of costs to the in-
dividual, to industry, and to society. A
drugmaybeonlyusefulinparticularsub-
setsofat-riskpatients,withtheDPP,asan
example, showing a particularly great ef-
fect of metformin in patients who were
younger and had higher BMI or fasting
glucose levels at baseline.
A special FDA public advisory com-
mittee held 1–2 July 2008 was asked
whether antidiabetes therapy without a
concerning cardiovascular safety signal
during phase 2–3 of development will be
required to conduct a long-term cardio-
vascular trial or to provide other equiva-
lent evidence to exclude unacceptable
cardiovascular risk; 14 committee mem-
bers voted in favor of, and two voted
against, requiring such tests. Based on
other discussions at the advisory commit-
tee meeting, Parks stated that A1C is still
considered a valid efﬁcacy end point for
antidiabetesdrugapproval,thattype2di-
abetes is a chronic disease requiring life-
longtherapy,thatlong-termsafetyproﬁle
is important for informed use, and that
while demonstration of cardiovascular
beneﬁt is not required, it is critical to en-
sure no cardiovascular harm. Presum-
ably, these preliminary considerations
could be applied to a trial of a drug for
diabetes prevention. Currently, “none of
thedrugsarelabeledforpreventionofmi-
crovascular or macrovascular outcomes”
but, rather, are labeled for reduction of
hyperglycemia. In discussion of Parks’
presentation, it was noted that Ratner’s
power calculations about the trial size
needed to show cardiovascular beneﬁt
wouldbelikelytoapplytoatrialdesigned
toshowlackofcardiovascularharm,such
that a 3-year study of a pre-diabetic pop-
ulation with a 0.5–1% annual cardiovas-
cular disease rate would require tens of
thousands of subjects to prove lack of a
40% increase in adverse events.
George Bray (Batton Rouge, LA) dis-
cussed the effect of weight loss drugs and
bariatric surgery in pre-diabetic and dia-
betic patients, reminding the audience
that “[in which fat depot] we put . . . the
fat makes a great difference.” The norepi-
nephrine, serotonin, and dopamine re-
uptake inhibitor sibutramine is effective
(27). Although weight loss is not main-
tained after placebo washout, it is with
ongoing treatment (28), and triglycerides
and LDL and HDL cholesterol all im-
proved over 18 months. Diabetic patients
also show weight loss with sibutramine
(29),butmoststudiesshowanincreasein
blood pressure (30) and, using meta-
analysis, glycemic improvement cannot
be demonstrated (31). Side effects in-
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constipation, tachycardia, and increase in
blood pressure.
Orlistat, an intestinal lipase inhibitor,
leads to loss of 30% of ingested fat and
appears to have additional glucose- and
cholesterol-lowering effects that last over
2 years (32), with loss of efﬁcacy if pla-
cebo is given. The 4-year XENDOS study
showedreductioninconversiontodiabe-
tes (33) (as did other studies [34]) with a
meta-analysis showing 61% reduction in
diabetes development and 72% reversion
of IGT to NGT, whereas this only oc-
curred in 49% of placebo-treated patients
(35). In diabetic patients, HDL and glu-
cose levels are consistently found to im-
prove (36); the drug was submitted to the
FDA as an antidiabetes drug but was not
approved for this indication. An interest-
ing study not cited by Bray, appearing af-
ter the conference, indicated that orlistat
mayreduceendogenousGLP-1levelsand
accelerate gastric emptying (37), suggest-
ing a mechanism by which its efﬁcacy
may be limited or, alternatively, that the
combination of orlistat with a drug in-
creasing GLP-1 levels or GLP-1 receptor
activation might be particularly effective.
A number of additional pharmaco-
logic approaches may be used for weight
loss (38). Topiramate, a carbonic anhy-
draseinhibitor,appearstoproduceongo-
ing weight loss over 12–15 months: a
study of diabetic patients showed im-
provementinglucoseandbloodpressure,
although HDL cholesterol was reduced
and the agent causes sedation and is no
longerbeingdeveloped(39).Rimonabant
is a cannabinoid receptor antagonist that
reduces food intake (40) and improves
waist circumference, weight, triglyceride,
HDL cholesterol, and blood pressure,
with the effect lost when the agent is dis-
continued. The ADAGIO lipids study of
803 individuals with atherogenic dyslipi-
demia showed increased HDL, decreased
triglycerides, decreased weight, and in-
creasedadiponectin—alltogreaterextent
than placebo—with decreased ALT and,
as ascertained with a computed tomogra-
phy scan, improvement in visceral adi-
pose tissue and liver fat. Diabetic patients
show these effects and show improve-
ment in A1C, “so it has a broader meta-
bolic effect” with both newly diagnosed
(41) and established (42) diabetes. In a
study of 839 individuals undergoing in-
travascular ultrasound, weight and total
(but not percent) atheroma volume de-
creased but discontinuation for anxiety
and depression was seen (a signiﬁcant
caution) and nausea rates tripled (43).
“Exenatide is complex,” Bray stated, be-
causeofitsrequirementforparenteralad-
ministration. He predicted that
“combinations will be eventually the way
we treat.”
Therehasbeentremendousgrowthin
the use of bariatric surgery (44). These
procedures improve glycemia in diabetic
and pre-diabetic patients (45). Gastric
banding, gastroplasty, and, to a greater
extent, gastric bypass procedures lead to
weight loss sustained over a 15-year fol-
low-up, with nonrandomized controlled
trial evidence that surgical treatment re-
ducesdevelopmentofdiabetestoadegree
proportional to the weight loss, lengthen-
ing life and reducing mortality (46). New
studies are assessing the beneﬁt of these
procedures at lower levels of obesity be-
ginningatBMI30kg/m
2,withevidenceof
beneﬁts for nondiabetic individuals with
BMI 30–35 kg/m
2 (47) and for individu-
als with BMI 30–40 kg/m
2 and diabetes
duration 2 years (48).
Bray pointed out that pharmacologic
and surgical treatments of obesity tend to
equally affect visceral and subcutaneous
fat, although the latter is more relevant
metabolically. Liposuction removing on
average 9 kg of subcutaneous fat has been
studied, with no change in glucose and
insulin levels, blood pressure, HDL cho-
lesterol, triglycerides, adiponectin, tumor
necrosis factor-, or interleukin-6, al-
though leptin decreased (49). In contrast,
with TZD use, despite increases in weight
and total body fat, visceral fat does not
increase and there is improvement in car-
diometabolic risk factors (50).
Jean-Louis Chiasson (Montreal, Can-
ada) reminded the audience that “at the
presenttimetherearenoharddataforthe
pharmacological treatment of pre-
diabetes.” Metformin reduces the rate of
diabetes development (51). In the DPP,
metformin was associated with weight
loss and reduced insulin resistance rather
than improving insulin secretion (52).
Beneﬁts were seen particularly in those
aged 25–44 years with BMI 35 kg/m
2
(reduced metabolic syndrome). Chiasson
discussed a Chinese multicenter study of
325 pre-diabetic sbjects randomized to
control, diet/exercise, acarbose, and met-
formin groups, with baseline BMI 25
kg/m
2 (53). Diabetes developed in 11.6%
of control subjects but in 4.1% of those
receivingmetformin.TheIndianDiabetes
Prevention Programme of 531 pre-
diabetic subjects with mean BMI 25
kg/m
2
found a reduction in diabetes inci-
dencefrom55%after4yearswithoutinter-
vention to 39% after lifestyle intervention,
metformin, or both; all interventions re-
duced diabetes by 28–29%. (54).
Studies with acarbose suggest an
overall beneﬁt similar to that with met-
formin. In the Chinese study, the risk of
diabetes development was reduced 83%
with acarbose (53). These ﬁndings were
conﬁrmed by the STOP-type 2 diabetes
study, in which there was 36% reduction
in likelihood of conversion from pre-
diabetes to diabetes occurring across all
ages, in both sexes, and those with BMI
30 or 30 kg/m
2 (55). Conversion
from IGT to NGT increased 1.42-fold, in-
sulin sensitivity improved by 16%, and
there was a smaller but signiﬁcant im-
provement in insulin secretion. Chiasson
reviewed the evidence of prevention of
cardiovascular disease outcomes in the
study (56), characterizing it “at best [as]
hypothesis-generating data, at worst...a
ﬂuke, so let’s not over-interpret.” A three-
cardiologist blinded adjudication com-
mittee conﬁrmed that 32 cardiovascular
disease events occurred in placebo sub-
jects but 15 in acarbose-treated trial par-
ticipants,withfavorabletrendsforangina
and revascularization and signiﬁcant re-
duction of myocardial infarction—after a
2-year lag period, suggesting a biologi-
cally relevant mechanism. If silent myo-
cardial infarctions were added, acarbose
showed additional beneﬁts over placebo,
contrary to the ﬁndings with regard to
pioglitazone in the PROactive study, in
which inclusion of silent myocardial in-
farction would have made the “principal
secondary end point” beneﬁt nonsigniﬁ-
cant. Acarbose increases ﬂow-mediated
brachial artery vasodilatation in the post-
prandial period (57), a potential mecha-
nism of beneﬁcial effect, and also reduces
markersofoxidativestress,inﬂammation,
and coagulation. “The evidence is over-
whelming,” Chiasson concluded, that
“type 2 diabetes can be prevented or de-
layed through lifestyle modiﬁcations or
pharmacological interventions. The ben-
eﬁcial effect is lost if the intervention is
discontinued whether it be lifestyle or
pharmacological.” The ongoing Acarbose
Cardiovascular Evaluation (ACE) trial
will randomize 7,500 patients with IGT
and acute cardiovascular disease to acar-
boseversusplacebo(58)tomorefullyad-
dress whether this is an agent that should
be administered in the treatment of
pre-diabetes.
Carl Pepine (Miami, FL) discussed
the diabetes risk associated with hyper-
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blood pressure treatments, noting in par-
ticular that thiazide diuretics have long
beenrecognizedtohaveunfavorablemet-
abolic effects. Hypertension is, he stated,
the main cardiovascular risk factor in the
U.S. Diabetes is a cardiovascular disease
riskequivalent(59)andisassociatedwith
increased mortality following acute coro-
nary syndrome (60). Glucose levels are
associatedwithgreaterriskofhospitaliza-
tion for individuals with congestive heart
failure, with a trend suggesting adverse
effect of IFG (61). The fasting glucose
level also is associated with risk of atrial
ﬁbrillation.Fewstudieshavecarriedouta
GTT, so there is little information about
the risk of IGT. Glucose intolerance may
inﬂuence left ventricular mass and wall
thickness, worsen atherosclerosis, increase
inﬂammation, interfere with nitric oxide
metabolism, and worsen endothelial apo-
ptosis and may simply be a marker of insu-
lin resistance rather than directly causing
adverse outcome.
Inastudyof795individualswithun-
complicated,initiallyuntreatedhyperten-
sion, followed for 15 years, new diabetes
was associated with a three- to fourfold
increase in cardiovascular events (similar
to the effect of established diabetes), after
a 3–5 year lag period. Left ventricular hy-
pertrophy was a particularly important
cardiovascular risk marker in this study,
and thiazide diuretic use was a signiﬁcant
diabetes risk factor (62). A meta-analysis
showed -blockers and thiazides to be
worse than placebo, calcium channel
blockers similar, and renin-angiotensin
system antagonists protective against dia-
betes (63). In a study of hypertensive in-
dividualsnothavingovertcoronaryartery
diseaserandomizedtoamlodipinewithor
without perindopril versus atenolol with
or without thiazide, new-onset diabetes
was more likely to occur in the latter
group, independent of other diabetes
risks such as fasting glucose, obesity, tri-
glycerides, and systolic blood pressure
levels(64).HigherHDLcholesterol,alco-
hol intake, and age 55 years reduced
likelihood of diabetes. In a study compar-
ing verapamil and trandolapril with
atenolol and a thiazide in patients with
established coronary disease, new-onset
diabetes was more common in the latter
group after a lag of several years (65).
Youngerageandhigheron-treatmentsys-
tolic blood pressure were associated with
greater risk of new-onset diabetes. Car-
diovascular beneﬁts were equivalent,
with or without prior myocardial infarc-
tion, in the primary analysis, but in mul-
tivariate analysis the verapamil-based
strategywaslessbeneﬁcialthanthatusing
atenolol (66); therefore, determining
which drugs are most appropriate should
not be based solely on diabetes risk. Pep-
ine discussed a number of relatively new
drugs to be considered: the vasodilating
-blockers nebivolol, dilevalol, celipro-
lol, and carvedilol; moxonidine, a selec-
tive imidazole II–receptor agonist that
lowers blood pressure with glycemic and
insulin-sensitizing beneﬁts; and ranola-
zine, an antianginal agent with antiar-
rhythmic effect on cellular sodium and
calciumtransport,whichmayreducenew
diabetes. He suggested that patients’ risk
proﬁle be considered and that thiazides
be avoided or used at the lowest possible
doses, and he suggested using either ACE
inhibitors or angiotensin receptor block-
ers“butnotbothofthemgiventheresults
of ONTARGET” (67).
Edwin Gale (Bristol, U.K.) asked,
“What advice should we give to people
with pre-diabetes?” He addressed the re-
lationship between pre-diabetes, diabe-
tes, and cardiovascular disease, pointing
out that the term “prediction” should not
be used as a synonym for “association.”
Pre-diabetes was ﬁrst mentioned, he said,
in the 1930s in association with obesity
and family history. Conn and Fajans dis-
cussed the pre-diabetes state some 30
years later as an approach to prevention,
suggesting that parameters of study other
than carbohydrate metabolism would be
of interest (68).
In type 1 diabetes, screening for high
risk based on family history, antibody
positivity, and glycemic abnormalities al-
lows high predictive power, offering a ra-
tional scheme of genetic risk, then
etiologic status, then target organ dys-
function, and ﬁnally system failure to of-
fer a 750-fold increase in risk prediction.
Fortype2diabetes,however,genetictest-
ing is much more modest in its ability to
predict risk. Over the range in BMI from
20 to 40 kg/m
2, there is a 100-fold
increase in diabetes risk, but there is pro-
gressive increase in weight with age, and
individuals developing diabetes have
considerable overlap with the nondia-
betic population. Obesity and obesity-
relatedstatessuchasmetabolicsyndrome
and its individual components are, again,
only modestly associated with diabetes.
Gale asked, then, how cutoff points can
be drawn, distinguishing statistical, clini-
cal, prognostic, and operational ap-
proaches (69). The ﬁrst Wold Health
Organization (WHO) expert committee,
in 1965, suggested establishing two lev-
els: fasting glucose 130 mg/dl as diag-
nostic of diabetes and 110 mg/dl of
nondiabetes, with the intermediate levels
considered borderline. A second WHO
committee, in 1981, used evidence that
there is an inﬂection point for microvas-
cular risk at a 2-h postload glucose of 200
mg/dl. The ADA 1997 statement sug-
gested the use of clinical information
based on association of fasting glucose
microvascular risk. Although there ap-
pears to be a point of inﬂection in micro-
vascular risk at fasting and 2-h postload
glucose levels of 126 and 200 mg/dl, ma-
crovascular risk appears to increase
linearly with increase in glucose, and the
2003ADAstatementappearstotakeasta-
tistical approach to the diagnosis of dia-
betes—which he suggested to be less
desirable than the other approaches.
Certainly, raised glucose is a marker
of cardiovascular risk, but Gale asserted
that there is no evidence that treatment of
pre-diabetes reduces risk and, hence, no
evidence base with which to justify spe-
ciﬁc glucose-lowering treatment for pre-
diabetes. The question, then, is one of
deﬁning pre-diabetes, given that the GTT
is admittedly less feasible in large popula-
tions while fasting glucose alone is clearly
lessuseful.AnalysisfromtheDiabetesEp-
idemiology: Collaborative Analysis of Di-
agnostic Criteria in Europe (DECODE)
dataset only showed a 29% overlap be-
tween the 1997 ADA deﬁnition and
WHOcriteria,suggestingthatthetwoap-
proaches identify different populations
(70).DECODEfoundmorecaseswiththe
1997deﬁnition,withGalenotingthatthe
ADA deﬁnition eliminates younger and
heavier individuals. Gale cautioned the
audience to avoid deﬁnitions resembling
Lewis Carroll’s Cheshire Cat, which “fade
away when you try to deﬁne them,” and
pointed out that, currently, “hyperglyce-
miadeﬁnespre-diabetesandpre-diabetes
deﬁnes hyperglycemia,” citing the Ger-
man psychiatrist Carl Wunderlich’s state-
ment: “A view which takes abstract
concepts as things, implying their actual
existence and at once treating them as en-
tities, is a logical blunder that has fre-
quently crept into medicine and
ﬂourished there.”
Gale suggested, then, that pre-
diabetes is not a real disease and that we
may “impoverish ourselves by going back
toIFGandIGT,”suchthatitmaybemore
appropriate to tell patients that their
bloodglucoseisraised,explainthatthisis
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risk factors aggressively with treatments
that do not raise glucose but not, at this
point, more “pseudo-precisely” charac-
terize glucose or offer treatment for some
but not all glucose levels not reaching the
criterion of diabetes. “There are so many
other things we can do,” he went on to
state, such as aggressively treating blood
pressure and lipids and administering as-
pirin, that we should be very cautious
about treating blood glucose at levels
where it is not clear that intervention is
beneﬁcial. “Clinical medicine needs indi-
vidualizing,” Gale continued, stating that
it is appropriate to closely follow blood
glucose and A1C levels and to recognize
that the best overall approach is lifestyle
modiﬁcation,withpharmacologicaltreat-
mentonlyifthatcannotbeaccomplished.
His personal preference is to add met-
formin if these parameters increase
progressively.
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